Table 1.
Patient characteristics.
| Characteristics | Data (n=87) |
|---|---|
| Age | 52.3±6.5 |
| Male, n (%) | 71 (81.6%) |
| BMI | 23.8±2.7 |
| Child score, n (%) | |
| Class A | 50 (58.8%) |
| Class B | 24 (28.2%) |
| Class C | 11 (13.0%) |
| HCC, n (%) | 65 (74.7%) |
| Hepatitis B (duration, months) | 229±125 (4–517) |
| Pre-transplant antiviral agent, n (%) | 81 (93.1%) |
| Duration (months) | 36±41 (1–33) |
| Pre-transplant HBV viral markers | |
| HBsAg (+), n (%), mean ±SD (IU/L) | 87 (100.0%), 6629.03±3013.99 |
| HBsAb (+), n (%), mean ±SD (IU/L) | 4 (4.6%), 30.74±14.86 |
| HBeAg (+), n (%), mean ±SD (Index) | 27 (31.0%). 17.59±49.28 |
| HBeAb (+), n (%), mean ±SD (Index) | 63 (72.4%), 0.23±0.32 |
| HBV DNA (+), n (%), mean ±SD (IU/mL) | 40 (45.9%), 285,123±923,308 |
| HBV mutation | 16 (18.4%) |
| HBV precore mutation | 10 (62.5%) |
| HBV core mutation | 16 (100%) |
| HBV surface mutation | 8 (50%) |
| HBV drug resistance mutation | 5 (31.3%) |
BMI – body mass index; HBV – hepatitis B virus; HBsAg – hepatitis B surface antigen; HBsAb – hepatitis B surface antibody; HBeAg – hepatitis B e antigen; HBeAb – hepatitis B e antibody.